PfSir2A controls the var virulence gene expression in malaria parasites. Inhibitors targeting PfSir2A are potential antimalarial agents. In the current study, 3-TYP and NR are identified as lead compounds for further inhibitor development.
The study focused on the development of new quinazoline hybrid antimalarials, emphasising the significance of the molecular hybridisation approach and identifying potent hit molecules for the development of new antimalarials.
The present study unveils a thorough reevaluation of diphenylmethylpiperazine and pyrazine-derived molecular hybrids, introducing them as a new class of antimalarials.
This review presents a detailed analysis of β-carbolines as promising multi-target antimalarial agents.
This study offers compounds (66 and 75) as a new class of antimalarials, which are active against ACT-resistant strains of the Plasmodium and target several proteins of malaria parasite including the PfGAP50 protein.